Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted therapies for non-small cell lung cancer (NSCLC) are limited to small patient populations.
• Exploring non-conventional cancer pathways like RNA editing is crucial for discovering new therapeutic targets.
• Identifying novel actionable genetic lesions can improve patient survival in NSCLC.

Purpose of the Study:

• To investigate the role of RNA editing, specifically the adenosine-to-inosine editing enzyme ADAR1, in non-small cell lung cancer.
• To determine if ADAR1 gene amplification is associated with cancer progression and patient outcomes in NSCLC.

Main Methods:

• Analysis of ADAR1 gene amplification, mRNA, and protein levels in NSCLC cell lines and primary tumors.
• Functional studies involving ADAR1 depletion and overexpression in cell culture and mouse models.
• Assessment of ADAR1's impact on RNA editing of target transcripts (e.g., NEIL1, miR-381).
• Correlation of ADAR1 gene amplification with clinical outcomes in early-stage lung cancer patients.

Main Results:

• ADAR1 gene amplification, increased mRNA, and protein levels were observed in NSCLC.
• Depletion of ADAR1 reduced tumorigenic potential, while overexpression enhanced it.
• ADAR1 overexpression increased editing frequencies of target transcripts NEIL1 and miR-381.
• ADAR1 gene amplification in early-stage lung cancer patients correlated with poor prognosis.

Conclusions:

• ADAR1 functions as an oncogene in non-small cell lung cancer, driven by gene amplification.
• Amplification-associated activation of ADAR1 alters RNA editing patterns and negatively impacts patient prognosis.
• ADAR1 represents a potential therapeutic target for a subset of NSCLC patients.